Moderna, a leading biotech company, is making significant strides in the development of various pipeline candidates, including mRNA-1010, an influenza vaccine showing superior efficacy compared to a GSK flu shot. The company’s COVID-19 vaccine, Spikevax, continues to drive revenue, albeit with a projected decline due to lower demand. Additionally, Moderna’s RSV vaccine, mResvia, recently received FDA approval and an expanded label for high-risk adults.
Investors are eagerly awaiting updates on the company’s marketing plans for these vaccines and regulatory progress for Spikevax targeting the LP.8.1 variant. Moreover, Moderna’s collaboration with Merck on intismeran autogene, a personalized cancer therapy, is being evaluated in pivotal phase III studies across multiple cancer indications. The upcoming earnings report is anticipated to provide further insights into Moderna’s growth trajectory and pipeline advancements.
Read more from finance.yahoo.com